Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).

Annals of the New York Academy of Sciences - 1 Nov 2006

Waza Masahiro, Adachi Hiroaki, Katsuno Masahisa, Minamiyama Makoto, Tanaka Fumiaki, Sobue Gen

Abstract excerpt

Heat shock proteins (HSPs) that function mainly as molecular chaperones play an important role in the folding and quality control of proteins. Compared with these chaperones, Hsp90 is unique in that it binds to substrate proteins, called Hsp90 client proteins. Hsp90 is involved in the folding, ac...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoquinones
Share to HSP90 Heat-Shock Proteins
Share to Lactams, Macrocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Motor Neurons

Share to Muscular Atrophy, Spinal

Share to Neurodegenerative Diseases

Share to Proteasome Endopeptidase Complex

Share to Receptors, Androgen

Source

Identifiers

PMID: 17185503
DOI: 10.1196/annals.1377.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17185503-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).PMID 17185503Read ↗

Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.Semantic proximity Read ↗

17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.Semantic proximity Read ↗

Translational Shift of HSP90 as a Novel Therapeutic Target from Cancer to Neurodegenerative Disorders: An Emerging Trend in the Cure of Alzheimer's and Parkinson's DiseasesSemantic proximity Read ↗

Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine DiseasesSemantic proximity Read ↗

Geldanamycin and its derivatives as Hsp90 inhibitors.Semantic proximity Read ↗

Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cellsSemantic proximity Read ↗

Hsp90 as a therapeutic target in prostate cancer.Semantic proximity Read ↗

A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T α-Synuclein Toxicity.Semantic proximity Read ↗

Heat shock protein 90Semantic proximity Read ↗

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.Semantic proximity Read ↗

17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy.Semantic proximity Read ↗

Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.